Global Humira 麻豆原创 Research Report 2025

Publication ID:

PB504258167

Publication Date:

May 2, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Humira was valued at US$ 14370 million in the year 2024 and is projected to reach a revised size of US$ 7907 million by 2031, growing at a CAGR of -8.3% during the forecast period.
Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, Rheumatoid Arthritis, psoriatic arthritis, Ankylosing Spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.
Humira is also used in adults and children to treat Crohn"s disease or juvenile idiopathic arthritis.
In 2014, in India, the first adalimumab biosimilar came to market at a price of $200. Two years later, another Indian drugmaker, Torrent Pharmaceuticals, launched a second biosimilar. Humira"s U.S. patent expired in 2016.
The classification of Humira includes Humira Syringe and Humira Pen. The proportion of Humira Syringe is about 78%.
Humira is widely used for Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn鈥檚 disease and other disease. The most proportion of Humira is for Ankylosing Spondylitis, and the proportion is about 43%.
USA is the largest market, with a sales market share nearly 65%. Following USA, Europe is the second largest market with the sales market share of 30%.
麻豆原创 competition will intense. AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen and Boehringer Ingelheim are the key manufacturters of Humira. AbbVie is the leader of this industry by 97% market shares.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Humira, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Humira.
The Humira market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Humira market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Humira manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Segment by Type
Humira Syringe
Humira Pen
Segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn鈥檚 Disease
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Humira manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Humira in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Humira 麻豆原创 Overview
1.1 Product Definition
1.2 Humira by Type
1.2.1 Global Humira 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Humira Syringe
1.2.3 Humira Pen
1.3 Humira by Application
1.3.1 Global Humira 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Ankylosing Spondylitis
1.3.3 Rheumatoid Arthritis
1.3.4 Crohn鈥檚 Disease
1.3.5 Others
1.4 Global Humira 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Humira Revenue 2020-2031
1.4.2 Global Humira Sales 2020-2031
1.4.3 Global Humira 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Humira 麻豆原创 Competition by Manufacturers
2.1 Global Humira Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Humira Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Humira Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Humira, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Humira, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Humira, Product Type & Application
2.7 Global Key Manufacturers of Humira, Date of Enter into This Industry
2.8 Global Humira 麻豆原创 Competitive Situation and Trends
2.8.1 Global Humira 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Humira Players 麻豆原创 Share by Revenue
2.8.3 Global Humira 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Humira 麻豆原创 Scenario by Region
3.1 Global Humira 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Humira Sales by Region: 2020-2031
3.2.1 Global Humira Sales by Region: 2020-2025
3.2.2 Global Humira Sales by Region: 2026-2031
3.3 Global Humira Revenue by Region: 2020-2031
3.3.1 Global Humira Revenue by Region: 2020-2025
3.3.2 Global Humira Revenue by Region: 2026-2031
3.4 North America Humira 麻豆原创 Facts & Figures by Country
3.4.1 North America Humira 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Humira Sales by Country (2020-2031)
3.4.3 North America Humira Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Humira 麻豆原创 Facts & Figures by Country
3.5.1 Europe Humira 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Humira Sales by Country (2020-2031)
3.5.3 Europe Humira Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Humira 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Humira 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Humira Sales by Region (2020-2031)
3.6.3 Asia Pacific Humira Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Humira 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Humira 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Humira Sales by Country (2020-2031)
3.7.3 Latin America Humira Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Humira 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Humira 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Humira Sales by Country (2020-2031)
3.8.3 Middle East and Africa Humira Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Humira Sales by Type (2020-2031)
4.1.1 Global Humira Sales by Type (2020-2025)
4.1.2 Global Humira Sales by Type (2026-2031)
4.1.3 Global Humira Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Humira Revenue by Type (2020-2031)
4.2.1 Global Humira Revenue by Type (2020-2025)
4.2.2 Global Humira Revenue by Type (2026-2031)
4.2.3 Global Humira Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Humira Price by Type (2020-2031)
5 Segment by Application
5.1 Global Humira Sales by Application (2020-2031)
5.1.1 Global Humira Sales by Application (2020-2025)
5.1.2 Global Humira Sales by Application (2026-2031)
5.1.3 Global Humira Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Humira Revenue by Application (2020-2031)
5.2.1 Global Humira Revenue by Application (2020-2025)
5.2.2 Global Humira Revenue by Application (2026-2031)
5.2.3 Global Humira Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Humira Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Company Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Humira Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AbbVie Humira Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Eisai
6.2.1 Eisai Company Information
6.2.2 Eisai Description and Business Overview
6.2.3 Eisai Humira Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Eisai Humira Product Portfolio
6.2.5 Eisai Recent Developments/Updates
6.3 Cadila Healthcare
6.3.1 Cadila Healthcare Company Information
6.3.2 Cadila Healthcare Description and Business Overview
6.3.3 Cadila Healthcare Humira Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Cadila Healthcare Humira Product Portfolio
6.3.5 Cadila Healthcare Recent Developments/Updates
6.4 Torrent Pharmaceuticals
6.4.1 Torrent Pharmaceuticals Company Information
6.4.2 Torrent Pharmaceuticals Description and Business Overview
6.4.3 Torrent Pharmaceuticals Humira Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Torrent Pharmaceuticals Humira Product Portfolio
6.4.5 Torrent Pharmaceuticals Recent Developments/Updates
6.5 Amgen
6.5.1 Amgen Company Information
6.5.2 Amgen Description and Business Overview
6.5.3 Amgen Humira Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Amgen Humira Product Portfolio
6.5.5 Amgen Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Company Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Humira Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Boehringer Ingelheim Humira Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Humira Industry Chain Analysis
7.2 Humira Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Humira Production Mode & Process Analysis
7.4 Humira Sales and 麻豆原创ing
7.4.1 Humira Sales Channels
7.4.2 Humira Distributors
7.5 Humira Customer Analysis
8 Humira 麻豆原创 Dynamics
8.1 Humira Industry Trends
8.2 Humira 麻豆原创 Drivers
8.3 Humira 麻豆原创 Challenges
8.4 Humira 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

AbbVie
Eisai
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.